Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer.
Hayashi K, Furuta M, Furusawa K, Hamaguchi T, Watanabe M, Inokuchi Y, Onuma S, Hashimoto I, Suematsu H, Nagasawa S, Kanematsu K, Yamada T, Notsu A, Ogata T, Oshima T, Machida N, Furuse J, Maeda S.
Hayashi K, et al. Among authors: furusawa k.
Anticancer Res. 2023 Jun;43(6):2831-2840. doi: 10.21873/anticanres.16452.
Anticancer Res. 2023.
PMID: 37247885